Kim, Joong Kyu,Yoo, Jin San,Lee, Sang Hoon,Lee, Weon Sup,Kim, Sung Woo,Shim, Sang Ryeol,Yoo, Jin Sang,Lee, Young Ae,Not Given,Byun, Sang Soon,Lee, Hyuk Joon,Kim, Do Yun,Kim, Yeun Ju,Choi, Jin Hee,Nahm
申请号：
AU2013348570
公开号：
AU2013348570A1
申请日:
2013.11.20
申请国别(地区):
AU
年份:
2015
代理人:
摘要：
The present invention relates to an antibody targeting VEGFR-2, and more particularly a dual-target antibody of novel form in which calcium-binding EGF-like domains 11 and 12 of human Notch1 are bound to the N-terminal of the Tanibirumab light chain, a gene coding for same, a recombinant expression vector comprising the gene, host cells that have been genetically modified by using the recombinant expression vector and a method of producing a dual-target antibody by culturing the host cells, a pharmaceutical composition comprising the dual-target antibody, and a method for measuring the DLL4 antagonist efficacy of the dual-target antibody wherein Notch 1 activity is measured by the co-culturing of human umbilical endothelial cells (HUVEC) and a cell strain expressing human DLL4(hDLL4). The dual-target antibody according to the present invention has the advantages that, by more effectively simultaneously disrupting signal transmission following two different pathways of VEGF/VEGFR-2 and DLL4/Notch1, it is possible to treat various diseases associated with vasculogenesis such as tumours and, more particularly, possible to overcome the resistance that occurs following the use of a neovascular therapeutic agent alone, and that, by directly targeting cancer stem cells, it is possible to fundamentally prevent the recurrence of cancer.
